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Original Article
GAT3 selective substrate L-isoserine
upregulates GAT3 expression and
increases functional recovery after
a focal ischemic stroke in mice
Maria EK Lie1,2, Emma K Gowing2, Nina B Johansen1,
Nils Ole Dalby1, Louise Thiesen1, Petrine Wellendorph1
and Andrew N Clarkson2,3
Abstract
Ischemic stroke triggers an elevation in tonic GABA inhibition that impairs the ability of the brain to form new structural
and functional cortical circuits required for recovery. This stroke-induced increase in tonic inhibition is caused by
impaired GABA uptake via the glial GABA transporter GAT3, highlighting GAT3 as a novel target in stroke recovery.
Using a photothrombotic stroke mouse model, we show that GAT3 protein levels are decreased in peri-infarct tissue
from 6 h to 42 days post-stroke. Prior studies have shown that GAT substrates can increase GAT surface expression.
Therefore, we aimed to assess whether the GAT3 substrate, L-isoserine, could increase post-stroke functional recovery.
L-Isoserine (38 mM or 380 mM) administered directly into the infarct from day 5 to 32 post-stroke, significantly increased
motor performance in the grid-walking and cylinder tasks in a concentration-dependent manner, without affecting infarct
volumes. Additionally, L-isoserine induced a lasting increase in GAT3 expression in peri-infarct regions accompanied by a
small decrease in GFAP expression. This study is the first to show that a GAT3 substrate can increase GAT3 expression
and functional recovery after focal ischemic stroke following a delayed long-term treatment. We propose that enhancing
GAT3-mediated uptake dampens tonic inhibition and promotes functional recovery after stroke.
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Introduction
Stroke is a leading cause of disability and death with
patients exhibiting varied levels of functional recovery.1
Despite this, no pharmacological treatment options
exist to promote functional recovery, beyond the use
of remedial therapies. The tissue region surrounding
the infarct, the peri-infarct, is a structurally intact but
functionally impaired region critical for recovery.
Targeting this region can facilitate plasticity and cor-
tical remapping resulting in the formation of new struc-
tural and functional circuits between related cortical
regions.2–4 The process of plasticity is highly influenced
by GABAA receptor signaling and tonic GABA-
mediated inhibition, which maintains and shapes the
level of neuronal excitability and facilitates the remap-
ping of brain regions.5–8 Accordingly, alterations in
GABAergic signaling and tonic inhibition are triggered
by an ischemic stroke in both animals and
humans.6,8–10 Of particular importance, dampening
extrasynaptic a5-containing GABAA receptors from
three to seven days post-stroke and onwards, but not
acutely within hours, increases motor functional
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recovery in animal stroke models.6,11 Further, these
studies parallel observations in human patients where
functional recovery correlates with decreased
GABAergic signaling.10,12
Although GABA agonists have failed to translate
into positive clinical outcomes promoting neuroprotec-
tion in humans,13 GABA modulation, and in particular
tonic inhibition, has attracted new attention as a puta-
tive approach for promoting recovery during the sub-
acute phase (3–7 days) after ischemia.6,8,11,14,15
Interventions targeting the sub-acute phase offers a
much broader therapeutic window than the thrombo-
lytic treatment by tissue plasminogen activator (t-PA),16
and most if not all patients will have been assessed and
available to receive the treatment.17 Recent clinical
advances have confirmed that decreasing tonic inhib-
ition by inhibiting a5-containing GABAA receptors
results in an increase in cortical excitability.15 We now
await outcomes from phase 2 trials to confirm if, indeed,
such treatments promote neural repair post stroke.18,19
Tonic inhibition is in most cases regulated at the
GABAA receptor level and little attention has been
given to GABA transporters (GATs),14 which can regu-
late ambient GABA levels and hence affect tonic inhib-
ition.6,20–22 The glial GABA transporter, GAT3, has
previously been suggested to contribute to an increase
in tonic inhibition, as after stroke there is decreased
expression and impairment of GAT3 function. By con-
trast, GAT1, the most abundant GAT in the brain,
displays unaffected expression and function.6,8,23
Therefore, GAT3 could be a target for regulating
tonic inhibition in ischemic stroke. An alternative
approach to using GAT inhibitors is to use substrate
inhibitors for GATs, which have been reported to
increase GABA uptake in neuronal and glial cultures
via an increase in the surface expression of GAT1 and
GAT3, respectively.24 We report here that a delayed
chronic administration of the GAT3 substrate, L-iso-
serine,25 from 5 to 32 days post-stroke, increases func-
tional recovery in mice in a concentration-dependent
manner. Furthermore, we demonstrate that L-isoserine
induces long-lasting effects by increasing the expression
of GAT3 in peri-infarct regions, which we hypothesize
contributes to a dampening of tonic inhibition and pro-
motes remapping of cortical networks.
Material and methods
In vitro studies
Materials. L-Isoserine, (S)-SNAP-5114, GABA, tiaga-
bine and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). NO-711 and
picrotoxin (PTX) were purchased from Tocris
Bioscience (Bristol, UK). [2,3-3H(N)]GABA (35.0Ci/
mmol), [2,2-3H(N)]taurine (19.1Ci/mmol), [2-3H]gly-
cine (47.0Ci/mmol) and [methylene-3H(N)]muscimol
(30.2Ci/mmol) were purchased from PerkinElmer
(Boston, MA, USA). [4-14C]creatine hydrate
(57.0mCi/mmol) was purchased from Biotrend (Ko¨ln,
Germany).
DNA encoding the human taurine transporter
(TauT) was kindly provided by Dr. Nanna MacAulay
(University of Copenhagen, Denmark). Dr. Robert J
Vandenberg (University of Sydney, Australia) gener-
ously provided DNA constructs encoding the human
glycine transporters, GlyT1 and GlyT2. Human creat-
ine transporter (CreaT) DNA was purchased from
Origene (Rockville, MD, USA). All were subcloned
into the pUNIV vector (Addgene, Cambridge, MA,
USA) as described earlier.26
Cell cultures and transfection. Mouse and human GATs
were stably expressed in HEK-293 and CHO cells,
respectively, and tsA201 cells were cultured as
described previously.27 tsA201 cells were transfected
with plasmid DNA (8mg per 10 cm dish) encoding
human GAT3-pcDNA5/FRT,28 human GAT3 epi-
tope-tagged extracellularly with the hemagglutinin
(HA) (GAT3-HA)29 and human TauT,26 using 40 ml
PolyFect transfection reagent according to the manu-
facturer’s protocol (Qiagen, West Sussex, UK).
Cortical astrocytes were isolated from one- to
two-day-old NMRI mice (Janvier Labs, Le Genest-
Saint-Isle, France) using the neuronal tissue dis-
sociation Kit (P) and anti-ACSA-2 Microbead Kit
according to manufacturer’s protocols (MACS
Miltenyi Biotec, Lund, Sweden) and cultured as
described previously.26
In vitro competition uptake of L-isoserine at recombinant SLC6A
transporters. The [3H]GABA competition uptake assay
at mouse and human GATs and in cortical astrocyte
cultures was performed as previously described.26–28
Cortical astrocyte cultures were pre-incubated prior to
the [3H]GABA assay with compounds diluted in
Hank’s Balanced Salt Solution (HBSS) supplemented
with 20mM HEPES, 1mM CaCl and 1mM MgCl,
0.1% DMSO (pH 7.4) for 60min at 37C in a humidi-
fied incubator with 5% CO2.
Further, Xenopus laevis oocytes recombinantly
expressing related SLC6A members, including GlyT1,
GlyT2, TauT and CreaT, were also used to assess the
specificity for the GATs.26 [3H]taurine competition
uptake assay was performed at human TauT transiently
expressed in tsA201 cells following the protocol for the
[3H]GABA competition uptake assay described previ-
ously27,28 with the exception of exchanging [3H]GABA
with 22 nM [3H]taurine for 5min.
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The FLIPR membrane potential assay. The FMP assay was
performed as previously described.27
[3H]Muscimol binding. The assay of [3H]muscimol bind-
ing to the GABAA receptors was performed as previ-
ously described.30
GAT3 surface expression in vitro. Surface expression of
GAT3-HA upon pre-incubation with GAT3 com-
pounds was determined using an ELISA against the
HA-epitope. tsA201 cells recombinantly expressing
GAT3 was used to ensure that there was a significant
difference in the signal between GAT3-HA and GAT3
on the day of assay. Cells were washed with HBSS sup-
plemented with 20mM HEPES, 1mM CaCl and 1mM
MgCl (pH 7.4) (HBSS-HEPES) and incubated with
compounds diluted in HBSS-HEPES to study the
effect of 5 to 120min pre-incubation and in growth
media to study the effect of the compounds following
24 and 48 h pre-incubation, at 37C in a humidified
incubator with 5% CO2. The cells were fixed with 4%
PFA, and 0.05% Triton X-100 was added when the
total pool of GAT3-HA (intracellular pool and surface
fraction) was determined. The cells were blocked for
60min in 3% skim milk, incubated 45min at room tem-
perature (RT) with anti-HA (anti-HA.11, 1:1000,
BioLegend, San Diego, CA, USA), washed and incu-
bated with a HRP-conjugated antibody (anti-mouse,
1:1500, P0447, Dako, Glostrup, Denmark) for 45min
at RT. SuperSignalTM ELISA Femto substrate
(ThermoFisher Scientific, Waltham, MA USA) was
added with PBS, and chemiluminescence was measured
on an EnSpire2300 Multilabel Reader (PerkinElmer,
Waltham, MA, USA). Chemiluminescence is depicted
as a percentage of the control response.
MTT assay. The viability of the compound-treated
tsA201 cells expressing GAT3-HA was tested using
MTT. Compound-treated cells were incubated with
0.5mg/ml MTT for 2 h at 37C in a humidified incuba-
tor with 5% CO2 and solubilized with isopropanol
before reading the absorbance at 550 nm on an
EnSpire2300 Multilabel Reader (PerkinElmer).
Slice preparation. Slices were prepared from C57BL/6 J
male mice (Janvier Labs, Le Genest-Saint-Isle,
France) aged 5 1 weeks and dissected as described
earlier31 with minor modifications in the carbonated
bicarbonate buffer, with the composition (mM):
NMDG (100), NaCl (26), KCl (2.5), NaH2PO4 (1.25),
Glucose (10), CaCl2 (1), MgCl2 (3), NaHCO3 (26),
kynurenate (1), ascorbate (0.3) and pyruvate (0.1).
Slices were stored in regular carbonated artificial cere-
brospinal fluid (ACSF) at 28–29C (composition as
above, with NMDG replaced by NaCl and without
kynurenate) and used for recordings in the period of
1–5 h after cutting.
Whole-cell patch-clamp electrophysiology. In the recording
chamber, slices were perfused at a speed of 2.8–3mL/
min with a modified carbonated ACSF at 33–34C and
osmolarity adjusted to 310 3 mOsm. Recording
ACSF contained in addition to storage ACSF: kynur-
enate (1mM), CGP54626 (1 mM), atropine (1 mM),
TTX (0.5 mM), strychnine (1 mM), A804598 (1 mM),
GABA (1 mM). Pyramidal neurons in layer 2/3 of the
cingulate cortex were visually identified under IR
video-microscopy and recorded from using borosilicate
pipettes (1.5/1.1 OD/ID mm) with a CsCl-based intra-
cellular solution of the composition (mM): CsCl (135),
NaCl (4), MgCl2 (2), EGTA (1), HEPES (10), ATP (2),
GTP (0.5), TEA (5), QX-314 (5), adjusted to pH 7.2
and 292 3 mOsm. Recording electrodes had a resist-
ance of 5–8 MOhm in this solution and recording of
baseline activity began 6–7min after establishing the
whole cell configuration. Recordings were made using
a Multiclamp 700A amplifier (Axon, Molecular
Devices, Sunnyvale, CA, USA), digitized at 10 kHz
on a 1322 digidata (Molecular Devices) and filtered at
3 kHz (8-pole Bessell). After stable baseline was
obtained, recordings consisted of 3min baseline, 6min
of NO-711, 6min of L-isoserine and 5min of PTX.
Neuron capacitance and series resistance (SR) were
noted every 3–4min and compensated 70% for changes
in SR. Neurons for which the SR changed >30%
during the recording were omitted.
Recordings were analyzed in pClamp/Clampfit and
Origin 9 (Molecular Devices). Holding current was
assessed in a 60 s interval at the end of each baseline
and drug period as the center of a single Gaussian of
points sampled at a 100Hz frequency. Differences in
tonic current upon drug perfusion are depicted as dif-
ference in holding current relative to baseline and nor-
malized to neuron capacitance. Data are based on
recordings from 8 cells/8 slices from four animals.
In vivo and ex vivo studies
Animals and surgical procedures. All in vivo procedures
described in this study were carried out in accordance
with guidelines on the care and use of laboratory ani-
mals set out by the University of Otago, Animal
Research Committee and the Guide for Care and Use
of Laboratory Animals (NIH Publication No. 85-23,
1996). All in vivo studies were approved by the
University of Otago Animal Ethics Committee and
are reported according to the ARRIVE (Animal
Research: Reporting In Vivo Experiments) guidelines.
Focal stroke was induced by photothrombosis in
young (2–4 months old) male C57BL/6J mice
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(Hercus Taieri Research Unit, Dunedin, New Zealand)
weighing approximately 25–29 g as previously
described.6 Under isoflurane anesthesia (2–2.5% in
O2), mice were placed in a stereotactic apparatus, the
skull exposed through a midline incision, cleared of
connective tissue and dried. A cold light source
(KL1500 LCD, Zeiss) attached to a 40 objective
giving a 2mm diameter illumination was positioned
1.5mm lateral from Bregma and 0.2ml Rose Bengal
solution (10 g/L in normal saline, i.p.: Sigma-Aldrich)
was administered. After 5min, the brain was illumi-
nated through the intact skull for 15min, while keeping
body temperature at 37.0 0.3C by a heating pad
(Harvard apparatus, Holliston, MA, USA).
Mice were housed under a 12 h light/dark cycle with
ad libitum access to food and water. All animals (36 in
total) were randomly assigned to a treatment group five
days post-stroke (shamþ vehicle (n¼ 6) and shamþ L-
isoserine high (n¼ 6); strokeþ vehicle (n¼ 8),
strokeþ L-isoserine low (n¼ 8) and strokeþ L-isoserine
high (n¼ 6)). All assessments were carried out by obser-
vers blinded to the treatment group.
Compound administration and processing of tissue. A micro-
osmotic pump (model 1004, administration for 28
days at 0.11ml per hour, Alzet, Cupertino, CA,
USA) was connected to a cannula, placed directly
into the infarct, and was implanted on the back of
the mice on day 5 post-stroke. L-isoserine was dis-
solved in sterile DPBS with 0.3% DMSO and admin-
istered at a concentration of 38 mM and 380 mM
corresponding to the IC50 and 10 IC50 values at
recombinant mouse GAT3 (Table S1, Supplementary
material). Control mice received the vehicle containing
DPBS with 0.3% DMSO. The mice were individually
housed after the implantation of the micro-osmotic
pump to avoid littermates tampering with the
pumps. On day 42 post-stroke, all mice were sacrificed
by transcardial perfusion with 4% PFA, brains
extracted and processed for cresyl violet staining and
immunofluorescent labeling.
Behavioral assessment. Recovery of forelimb motor func-
tion was determined by the cylinder and grid-walking
tasks to assess their exploratory behavior and walking,
respectively, as previously reported.6 The mice were
tested approximately seven days prior to stroke to
establish a baseline performance level and then after
7, 14, 28 and 42 days post-stroke at approximately
the same time each day. Observers blinded to the treat-
ment group scored behaviors as previously described.6
Immunofluorescent labeling of GAT3 and GFAP and infarct
volume. Immunofluorescent labeling of GAT3 and
GFAP was performed 42 days post stroke. Brain sec-
tions, every sixth section through the stroke with
a thickness of 30 mm, were rinsed in tris buffered
saline (TBS) and transferred to 1% sodium tetraborate
in TBS for 20min at RT. The sections were blocked for
60min in TBS containing 5% goat and donkey serum
with 0.3% Triton X-100 and incubated in TBS with 2%
goat and donkey serum and 0.3% triton X-100 contain-
ing primary polyclonal antibodies (rabbit anti-mouse
GAT3, 1:100, AB1574 and chicken anti-mouse
GFAP, 1:3000, AB5541, Millipore, Darmstadt,
Germany) for 24–48 h at 4C. The rinsed sections
were incubated for 2 h at RT in the dark in TBS with
2% normal serum and 0.3% triton X-100 containing
appropriate fluorescent secondary antibodies (anti-
rabbit 1:1000, 711-485-152, Abacus ALS, Auckland,
New Zealand; anti-chicken 1:1000, SA5-10071,
ThermoFisher Scientific) and nuclear stained in
Hoechst (1:1000, Sigma-Aldrich) in TBS for 5min at
RT. Images were taken with an Olympus BX61 micro-
scope, and two sections from each animal were included
in the analysis. Changes in GAT3 intensity/cell and
GFAP staining were investigated at day 42 post-
stroke in layers 2/3 and 5 in the peri-infarct and
400 mm and 800 mm from the peri-infarct in 6 squares
of 90 180 mm. Using the software FIJI Image J
(National Institutes of Health, USA), the integrated
density value (IDV) was measured in all six regions of
interest (ROIs) on duplicate slides across the three
channels. Using the blue channel, a selection of at
least 10 representative nuclei in the ROI were outlined
and measured for integrated density. Dividing the blue
channel IDV of each ROI by the mean nucleus IDV
gives the average number of cells present in each
ROI. The fluorescent intensity of the GAT3 is
expressed as a per cell measure by dividing the IDV
of each ROI by its respective average cell number.
GFAP staining is expressed as IDV only. Infarct volumes
were determined 42 days post-stroke using cresyl violet
staining and Image J analysis by an observer blinded to
the treatment groups.6 The analysis is based on obtaining
measurements from every sixth section through the
entire infarct (area in mm2), and infarct volume was
quantified as follows: infarct volume mm3
¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
area mm2  section thickness section interval
p
. All
analyses were performed by an observer blinded to the
treatment groups.
GAT3 Western blotting. Another group of C57BL/6J male
mice (2–4 months old) were subjected to a photothrom-
botic stroke as described to investigate GAT3 expres-
sion in naı¨ve animals and animals subjected to stroke.
The animals were sacrificed by a pentobarbital over-
dose, followed by rapid extraction of the brain after
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1, 3 and 6 h and 1, 3, 7, 14 and 28 days post-stroke, to
determine the temporal change in GAT3 levels com-
pared to sham operated mice. The brains were cut on
a cryostat (CM1860, Leica) at 20C from anterior to
posterior, and the top quadrant of the left hemisphere
containing the peri-infarct and surrounding tissue were
collected. Protein was purified using RIPA-buffer sup-
plemented with cOmpleteTM and homogenized using a
bullet blender.
Western blotting was performed using theNuPAGE
system from Invitrogen (Carlsbad, CA, USA). Protein
samples mixed with 2 Laemmli with 0.1 M DTT were
sonicated for 5–10 s and left at RT for 10min before
loading. Ten micrograms of protein was loaded in 4–
12% Bis-Tris gels and separated by SDS PAGE for
60min at 170–180V. The gel was blotted on a PVDF
membrane (ThermoFisher Scientific) at 25–30V for
60min. The rinsed membranes were blocked 60min in
TBS containing 5% skimmed milk. The top part of the
membranes was incubated with blocking buffer contain-
ing the polyclonal GAT3 antibody (rabbit anti-mouse
GAT3, 1:1000, AB1574, Millipore) and the bottom
part of the membranes with the monoclonal glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) antibody
(mouse anti-mouse GAPDH, 1:12000, NB600-502SS,
Biologicals, Littleton, CO, USA) overnight at 4C. The
rinsed membranes were incubated with appropriate
HRP-conjugated secondary antibodies (anti-rabbit,
1:2000, A16096, ThermoFisher Scientific; anti-mouse,
1:2000, P0447, Dako) for 60min at RT, rinsed and incu-
bated with AmershamTM ECLTM Prime Western
Blotting Detection Reagent (GE Healthcare
Biosciences, Pittsburg, PA, USA) for 4min prior to the
detectionof chemiluminescence usingFlourChemHD2
(Alpha Innotech, San Leandro, CA, USA). Image J was
used to quantify optical density using GAPDH as a ref-
erence, which was unaffected by the stroke and stably
expressed at all time points. Each group contained 5–6
animals with 1–2 technical replicates.
Statistical analysis. All statistical analyses were performed
using GraphPad Prism (version 7.0c, San Diego, CA,
USA). One-way and two-way ANOVA followed by
Dunnett’s multiple comparison test and unpaired t-
test were used when as appropriate and specified
accordingly. P< 0.05 was considered statistically
significant.
Group sizes for the behavioral analysis were deter-
mined by power analysis calculations using the G
Power Software (version 3.1.5) based on data obtained
previously in the grid-walking and cylinder tasks.6,32,33
The following parameters: a¼ 0.05, effect size¼ 1.5,
two-sided for behavioral experiments were used. To
ensure a power >80%, we included six animals in
each of the two sham groups and 6-8 animals in each
of the stroke groups.
Results
GAT3 protein expression levels are decreased in the
peri-infarct and surrounding region
Previous studies have shown that GAT3 protein levels
are decreased in the peri-infarct cortex after a photo-
thrombotic stroke to the motor cortex coinciding with
an increase in tonic inhibition.6,8 To extend the regional
and temporal pattern of GAT3 expression after stroke,
we examined GAT3 protein expression in the peri-
infarct cortex of mice after a photothrombotic stroke
to the forelimb motor cortex. Using Western blotting,
we found that the GAT3 protein expression decreased
in the peri-infarct cortex and surrounding tissue from
1h onwards, reaching a significant reduction by 6 h,
with a maximal decrease in expression (46% decrease)
observed seven days post-stroke (Figure 1(a) and (b)).
A small non-significant decrease in expression was
observed at 14 and 28 days post-stroke. For the
Western blotting, we isolated the top quadrant of the
brain containing the peri-infarct and surrounding tissue
(Figure 1(b)). As a result, we were not able to assess
region-specific changes in GAT3 expression, which
could also be masked given the way the tissue was col-
lected. Thus, to more accurately assess the GAT3
expression specifically in the peri-infarct cortex and
subsequent regions, we investigated immunofluores-
cent staining of GAT3 42 days post-stroke in layers
2/3 and 5 in the peri-infarct and 400 mm and 800 mm
away from the peri-infarct region. We show that the
photothrombotic stroke induced long-lasting effects
after 42 days primarily in the peri-infarct cortex,
where the GAT3 expression was significantly
decreased by 48% and 63% in layers 2/3 and 5,
respectively (GAT3 intensity/cell: shamþ vehicle vs.
strokeþ vehicle, layer 2/3: 2436 vs. 1253 and layer 5:
3916 vs. 1445), as well as in the subsequent regions in
layer 5 by 28–41% (GAT3 intensity/cell: shamþ vehi-
cle vs. strokeþ vehicle, 400mm: 3733 vs. 2211 and
800 mm: 3439 vs. 2463) (Figure 1(c)). Although
GAT3 protein expression levels determined by
Western blotting were not different from sham levels
after 14 days, it is clear from the immunofluorescent
staining of GAT3 that a stroke to the motor cortex
did indeed induce long-lasting decreases in GAT3
expression. These long-lasting changes in GAT3 were
mainly in the peri-infarct region up to 800 mm away
from the infarct and may very well affect the tonic
currents in these given regions accordingly as long as
42 days post-stroke.
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In vitro characterization of the GAT3
substrate L-isoserine
Supported by our findings in Figure 1, impaired GAT3-
mediated uptake leads to a chronic increase in tonic
inhibition in the peri-infarct cortex hindering functional
recovery.6 Previous studies have shown that GAT sub-
strates can enhance GABA uptake in neuronal and glial
cultures via an increase in the surface expression of
GAT1 and presumably also GAT3.24,34,35 The only
GAT3 substrates currently available are L-isoserine
and 3-guanidinopropionic acid (3-GPA),36 but the
in vivo usability of 3-GPA is limited as it induces
weight loss in animals37 and inhibits both the TauT
and the CreaT (data not shown). Thus, we chose to
use L-isoserine to investigate if a GAT3 substrate
could enhance the expression of GAT3 and increase
functional recovery after a motor cortex stroke in
mice. To determine the dosing of L-isoserine, we first
determined the selectivity profile of L-isoserine at
recombinant GATs expressed in cell lines using a stand-
ard [3H]GABA uptake assay. We show that L-isoserine,
by competing with [3H]GABA, has an IC50 value of
38.2 mM at mouse GAT3 displaying >26-fold and
>19-fold selectivity over GAT1 and BGT1, respect-
ively. However, L-isoserine has a similar potency at
GAT2 as GAT3, making it a GAT2/3 preferring sub-
strate inhibitor (Table S1, Supplementary material),
similar to 3-GPA, although L-isoserine does not inhibit
CreaT (Table S2, Supplementary material).36 For com-
parison, we also determined the profile of L-isoserine on
human GATs and found the selectivity profile of L-
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Figure 1. Temporal changes in GAT3 expression in the peri-infarct region and surrounding tissue after a photothrombotic stroke to
the motor cortex in male mice. (a) Western blotting data showing that GAT3 expression decreased significantly from 6 h to 7 days
post-stroke including the depiction of the outlined region isolated for Western blotting containing the peri-infarct and surrounding
tissue (black box). (b) Representative Western blots of GAT3 and GAPDH. One-way ANOVA followed by Dunnett’s multiple
comparison test comparing sham to the different time points post-stroke. *P< 0.05, **P< 0.01, ***P< 0.001 (n¼ 6 for sham and 1, 3
and 6 h and 1, 14 and 28 days, n¼ 5 for 3 and 7 days). (c) GAT3 intensity/cell 42 days post-stroke in the peri-infarct region and
þ400 mm and þ800mm from the peri-infarct in layers 2/3 and 5 (see Figure 4(a)). GAT3 intensity/cell was significantly decreased in the
peri-infarct in layers 2/3 and 5 and outside the peri-infarct in layer 5, but not in layer 2/3. Two-way ANOVA with stroke and region as
independent factors and region as repeated measures followed by Dunnett’s multiple comparison test comparing shamþ vehicle to
strokeþ vehicle in the specific regions. **P< 0.01, ***P< 0.001 (n¼ 6). Box plot (boxes, 25–75%; whiskers, minimum and maximum;
lines, median).
GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
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isoserine to be retained at the human orthologues
(Table S1, Supplementary material). Using the FMP
assay, we verified that L-isoserine is indeed a substrate
for GAT3 with a potency similar to GABA itself (EC50
(pEC50 S.E.M.): 10.7mM (4.97 0.04), Figure S1(a),
Supplementary material) and will be transported by
GAT3 in competition with endogenous GABA
making it a substrate inhibitor. Despite L-isoserine’s
structural resemblance to GABA, L-isoserine has very
weak affinity for the GABAA receptors
(IC50> 1000 mM in [
3H]muscimol binding, Figure
S1(b), Supplementary material).
The GAT2/3 inhibitor (S)-SNAP-5114 has been
shown to increase tonic inhibition,6,21,22,38 while the
effect of a GAT3 substrate inhibitor on tonic currents
is unknown. To confirm that GAT3 interaction leads to
modulation of tonic inhibition in cortex, we tested the
effect of L-isoserine on tonic currents in layer 2/3 pyr-
amidal neurons. Indeed, by means of whole-cell patch-
clamp recordings on slices from naı¨ve mice, we show
that L-isoserine is able to modulate tonic currents via
GABAA receptors as the change in tonic currents was
abolished in the presence of PTX (Figure 2). Therefore,
L-isoserine exposure, being a substrate inhibitor of
GAT3 with negligible binding to GABAA receptors at
1000 mM, plausibly modulates tonic currents by com-
peting with GABA present during the recordings for
GABA uptake via GAT3, hence increasing ambient
GABA levels.
Due to the structural resemblance of L-isoserine to
GABA, which has a zwitterionic nature at physiological
pH, brain penetration is unlikely.36 Thus, in the subse-
quent experiments, we administered L-isoserine directly
into the infarct, which at the same time eliminates any
GAT2-mediated inhibition, since GAT2-mediated
GABA uptake is absent from brain parenchyma.39
The GAT3 substrate L-isoserine increases
post-stroke recovery
Having verified that GAT3 expression is subjected to
long-lasting changes following an ischemic stroke, we
wanted to investigate the modulatory role of GAT3 in
stroke recovery using L-isoserine. Therefore, we set out
to investigate the effect of a delayed chronic adminis-
tration of L-isoserine on functional recovery after a
photothrombotic focal stroke to the motor cortex.
L-isoserine was administered from five days post-
stroke, the beginning of the critical period for neuro-
plasticity in rodents post-stroke,40 with administration
continuing for 28 consecutive days. Significant forelimb
motor deficits contralateral to the hemisphere with
stroke were observed throughout the 42 days in the
grid-walking and cylinder tasks in vehicle-treated ani-
mals with minor spontaneous recovery (Figure 3).
Thus, chronic impairment of the affected forelimb
was observed in response to a photothrombotic stroke
mimicking what others have reported in humans.17
Chronic delayed treatment with the high concentration
of L-isoserine increased motor performance of the
affected forelimb from day 7 in the grid-walking task
and from day 14 in the cylinder task. The low concen-
tration of L-isoserine increased motor performance
from day 14 in both behavioral tasks (Figure 3) illus-
trating a concentration-dependent improvement in
motor function in response to L-isoserine treatment.
The total increase after 42 days for the low and high
concentration compared to the vehicle-treated mice,
***
(a) (b)
Figure 2. Tonic currents in pyramidal neurons in layer 2/3 and the effect of L-isoserine. Whole-cell patch-clamp recordings were
made on slices from naı¨ve mice. (a) Representative traces showing the tonic inhibitory currents and the sequential inhibition of GAT1
by NO-711 and GAT3 by L-isoserine followed by blockade of the GABAA receptors by picrotoxin (PTX) as indicated by the horizontal
bars. (b) The GAT1 inhibitor NO-711 and L-isoserine both enhanced the tonic currents via GABAA receptors as the change in tonic
currents were abolished by PTX. Unpaired t test comparing the change in tonic currents in response to NO-711 and L-isoserine.
***P< 0.001. Recordings are from 8 cells/8 slices from 4 mice. Box plot (boxes, 25–75%; whiskers, minimum and maximum; lines,
median).
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respectively, was 44% and 53% in the grid-walking task
(forelimb foot faults relative to total steps taken (%):
strokeþ vehicle vs. strokeþ L-isoserine, low: 43% vs.
27% and high 43% vs. 26%, Figure 3(a)) and 36%
and 39% in the cylinder task (time spent on left fore-
limb relative to right (%): strokeþ vehicle vs.
strokeþ L-isoserine, low: 88% vs. 49% and high: 88%
vs. 41%, Figure 3(b)). No signs of seizures or seizure-
like behavior were observed in any of the mice
throughout the 42 days and no changes in infarct vol-
umes upon L-isoserine treatment were observed (Figure
3(c)).
L-Isoserine increases the GAT3 intensity/cell outside
the peri-infarct region
To investigate whether L-isoserine increased GAT3
expression in the stroke animals, we assessed the
(a)
(b)
(c)
Figure 3. Motor function pre-op (before) and 7, 14, 28 and 42 days after a photothrombotic stroke and infarct volume. Motor
function was assessed by analyses of (a) foot faults and (b) forelimb asymmetry in the grid-walking and cylinder tasks, respectively.
Significant forelimb deficits (P< 0.001), contralateral to the hemisphere with stroke, were observed for at least 42 days post-stroke on
both behavioral tasks. Chronic treatment with the high concentration of L-isoserine from day 5 and for 28 consecutive days (gray box)
improved motor function from day 7 and onwards in the grid-walking task and from day 14 in the cylinder task. The low concentration
of L-isoserine improved motor performance in both tasks from day 14. Two-way ANOVA followed by Dunnett’s multiple comparison
test with time and treatment as independent factors and time as repeated measures. # P< 0.001 strokeþ vehicle compared to
shamþ vehicle, *P< 0.05, **P< 0.01, P< 0.001, strokeþ vehicle compared to strokeþ L-isoserine low or high (shamþ vehicle (n¼ 6)
and shamþ L-isoserine high (n¼ 6); strokeþ vehicle (n¼ 8), strokeþ L-isoserine low (n¼ 8) and strokeþ L-isoserine high (n¼ 6)).
Data are expressed as mean SD. (c) Infarct volume 42 days post-stroke was unaffected by L-isoserine treatment. One-way ANOVA
followed by Dunnett’s multiple comparison test comparing strokeþ vehicle to strokeþ L-isoserine low or high (strokeþ vehicle
(n¼ 8), strokeþ L-isoserine low (n¼ 8) and strokeþ L-isoserine high (n¼ 6)). Box plot (boxes, 25–75%; whiskers, minimum and
maximum; lines, median).
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GAT3 expression using immunofluorescent labeling 42
days post-stroke, after the animals had completed the
last behavioral tasks, corresponding to 10 days after
discontinuing the L-isoserine treatment. We found
that L-isoserine treatment generally increased GAT3
expression by 33–53% at the low concentration and
12–37% at the high concentration in different regions
(Figure 4). At the low concentration of L-isoserine, this
increase was significant in layer 5, 400 mm and 800 mm
from the peri-infarct where GAT3 expression was
increased by 53% and 37%, respectively (GAT3 inten-
sity/cell: strokeþ vehicle vs. strokeþ L-isoserine,
400 mm: 2211 vs. 3381 and 800 mm: 2463 vs. 3379).
With immunofluorescent GAT3 staining, we studied
the effect of L-isoserine at a fixed time point 10 days
after the treatment was discontinued and in relation to
the total pool of GAT3. We next wanted to investigate
if L-isoserine had an effect on the total GABA uptake
or GAT3 surface expression in vitro. Using cerebral
astrocyte cultures, we found no effect on the total
[3H]GABA uptake after 60min pre-incubation with L-
isoserine (10–200 mM) (Figure 5). These data indicate
that short-term exposure to L-isoserine, although being
a substrate inhibitor of GAT3 as demonstrated in the
FMP assay, does not induce lasting changes in GAT3
activity or in GAT3 surface expression in astrocyte cul-
tures. This is in contrast to previous findings with the
GAT1/3 substrate nipecotic acid, which has been found
to slow down the internalization of GAT1 by a direct
transporter-dependent mechanism requiring direct
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Figure 4. GAT3 intensity/cell and GFAP expression 42 days post-stroke. (a) Representative staining of GAT3 and GFAP and the six
squared regions, where the GAT3 intensity/cell and GFAP intensity were determined; peri-infarct (1 and 4) and 400 mm (2 and 5) and
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increased post-stroke in the peri-infarct compared to shamþ vehicle at day 42. This increase is reduced by the high concentration of L-
isoserine in layer 5, but not in layer 2/3, compared to strokeþ vehicle layer 5, while the low concentration had no effect. Two-way
ANOVA with treatment and region as independent factors and region as repeated measures. *P< 0.05, **P< 0.01, ***P< 0.001
(shamþ vehicle (n¼ 6) and shamþ L-isoserine high (n¼ 6); strokeþ vehicle (n¼ 6), strokeþ L-isoserine low (n¼ 8) and strokeþ L-
isoserine high (n¼ 6)). Box plot (boxes, 25–75%; whiskers, minimum and maximum; lines, median).
GFAP: glial fibrillary acidic protein;
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tyrosine phosphorylation of GAT1.24 Interestingly,
more chronic exposure to L-isoserine did result in an
increased GAT3 expression as indicated by immunohis-
tochemistry on tissue collected after completion of the
behavioral testing. This indicates that substrate inhibi-
tors of GAT3 can alter the expression of GAT3 in vivo.
However, we did find that pre-incubation with the
GAT3 inhibitor (S)-SNAP-5114 decreased the total
[3H]GABA uptake (Figure 5), in line with previous
findings,24 suggesting that GAT3 is subjected to the
same kind of regulation as GAT1, as revealed by the
GAT1 inhibitor tiagabine, when it comes to inhibitors
but not substrate inhibitors. This is supported by a
decreased total [3H]GABA uptake in response to high
GABA concentrations (Figure 5).
To investigate if the surface expression of GAT3,
which, in large, dictates ambient GABA levels in vivo,
is modulated by L-isoserine, we turned to recombinant
settings using ELISA and tsA201 cells transiently
expressing an extracellularly epitope-tagged trans-
porter, GAT3-HA. We found that L-isoserine had no
effect on the surface expression of GAT3 in vitro within
a period of 5–120min, 24 or 48 h exposure (Figure 6),
although an intracellular pool of GAT3-HA was avail-
able (data not shown). In addition, GABA and (S)-
SNAP-5114 had no effect on GAT3 surface expression,
although we were unable to study the long-term effects
of (S)-SNAP-5114 due to toxic effects (observed as a
decreased viability of the cells after 24 h) (Figure 6).
L-Isoserine modulates the glial scar
Last, we wanted to investigate if L-isoserine has an
effect on the glial scar. The glial scar has many roles
after a stroke has occurred, both as a regulator of the
inflammatory response and in relation to axonal
sprouting, which is critical for cortical remapping.41–43
We observed a clear up-regulation of the GFAP expres-
sion 42 days post-stroke compared to sham-operated
mice in the peri-infarct in layer 2/3 and 5 (Figure
4(c)). Chronic treatment with the high concentration
of L-isoserine decreased the GFAP expression in the
peri-infarct in layer 5, while the low concentration
had no effect (Figure 4(c)). The GFAP expression out-
side the peri-infarct was not increased in the stroke ani-
mals compared to shams and was not affected by L-
isoserine treatment (data not shown).
Discussion
Recent studies have shown that tissue adjacent to the
stroke, the peri-infarct cortex, is a region of heightened
plasticity and contributes to the limited capacity of the
brain to repair following a stroke.17,43–45 The peri-
infarct cortex is a region where patterns of evoked neur-
onal activation shift, correlating to improved functional
recovery.33,43 This process involves changes in brain
excitability, which underlies changes in the way the
brain represents motor and sensory function. In par-
ticular, a reduction in cortical inhibition promotes
recovery of function in peri-infarct cortex by facilitat-
ing the formation of new functional and structural cir-
cuits to enhance motor remapping.46 Consistent with
this, we have recently shown that a delayed reduction
in GABA-mediated tonic inhibition, by inhibiting
extrasynaptic GABAA receptors, can increase the
recovery of motor function,6,47 and that the changes
in GABA signaling in the peri-infarct region and result-
ant increase in tonic inhibition after an ischemic stroke
is in part due to changes in GAT3 expression and
function.6
GAT3 expression is decreased post-stroke
In the present study, we show that GAT3 is subjected to
long-lasting changes in response to ischemia, primarily
affecting the cells found in close proximity to the ische-
mic core. In this area, GAT3 expression is already
down-regulated after 6 h and remains suppressed 42
days post-stroke, indicating that it is most likely the
palisading astrocytes, which form the glial scar, that
display a reduced GAT3 expression. These temporal
changes in GAT3 levels match the reported change in
tonic inhibition,6 further supporting the hypothesis that
impaired GAT3-mediated uptake is contributing to the
Figure 5. Total [3H]GABA uptake in cortical astrocyte cul-
tures. Pre-incubation (60 min) with L-isoserine had no effect at
the concentrations tested, while GABA (100 and 200mM), (S)-
SNAP-5114 (5,10 and 50mM) and tiagabine (5, 10 and 100 mM)
decreased the total [3H]GABA uptake significantly. Experiments
were performed in triplicates in five independent experiments
except for (S)-SNAP-5114 and tiagabine at 5mM and L-isoserine
and GABA at 200 mM that were tested in two independent
experiments. One-way ANOVA followed by Dunnett’s multiple
comparison test comparing all compounds to the control.
*P< 0.05, **P< 0.01, ***P< 0.001. Box plot (boxes, 25–75%;
whiskers, minimum and maximum; lines, median).
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(a) (b)
(c)
(d)
(e) (f)
Figure 6. GAT3 surface expression in tsA201 cells recombinant expressing GAT3-HA and their corresponding cell viability. (a to c)
The surface expression of GAT3-HA was assessed by ELISA, (d to f), while cell viability after pre-incubation at different time points
with the compounds was assessed by MTT. (a to c) 5 min to 48 h pre-incubation with L-isoserine and GABA had no effect on the
surface level of GAT3 compared to control. (a) (S)-SNAP-5114 also had no effect on GAT3 surface expression after 5–120 min pre-
incubation, (e and f) while we could not see any long-term effect of (S)-SNAP-5114 (50 mM) due to toxic effects after 24 h.
Experiments were performed in triplicate in at least three independent experiments. Two-way ANOVA with treatment and time as
independent factors and no repeated measures followed by Dunnett’s multiple comparison test comparing all compounds to the
control (5–120 min) and one-way ANOVA (24 and 48 h) followed by Dunnett’s multiple comparison test comparing the effect of the
compound to the control. *P< 0.05, ***P< 0.001. Box plot (boxes, 25–75%; whiskers, minimum and maximum; lines, median).
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chronic elevation in tonic inhibition after ischemia. We
also show that changes in the total pool of GAT3 cor-
relates with equal changes in tonic inhibition and that
the down-regulation of GAT3 precedes the changes in
tonic inhibition reported by Clarkson et al.6 and
extends for as long as 42 days post-stroke, much
longer than previous thought.6 Yet, we cannot exclude
that other sources may contribute to the increase in
ambient GABA levels including reactive astrocytes,
which have been reported to be able to produce and
subsequently release GABA via the anion channel
bestrophin1 (Best1)48 and GAT3 efflux.38,49
Delayed treatment with a GAT3 substrate,
L-isoserine, increases GAT3 expression and
post stroke recovery
With GAT3 being a direct regulator of ambient GABA
levels and tonic inhibition14 and being involved in the
pathology of an ischemic stroke,6,8 we wanted to inves-
tigate the therapeutic potential of a GAT3 substrate
inhibitor. We are the first to show that the GAT3 sub-
strate inhibitor, L-isoserine, increases functional recov-
ery of the affected forelimb in a concentration-
dependent manner from day 7 without any rebounds
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Figure 7. Schematic summary of key results and the proposed hypothesis stating how L-isoserine increases functional recovery after
a photothrombotic stroke. (a) A focal stroke to the motor cortex decreases GAT3 expression in the peri-infarct and surrounding
regions from 6 h to 42 days post-stroke (indicated by a lighter shading in a subset of GAT3) and impairs motor function from 7 to
42 days post-stroke (strokeþ vehicle compared to shamþ vehicle). Also, we have previously shown that tonic inhibition is increased in
the peri-infarct region from 3 to 14 days after a focal stroke due to impaired GAT3-mediated GABA uptake.6 (b) Chronic L-isoserine
treatment increases GAT3 expression at day 42 in stroke animals (indicated by a subset of GAT3 being larger), 10 days after the
treatment was discontinued, and alongside increases functional recovery from day 7 and onwards (strokeþ vehicle compared to
strokeþ L-isoserine high). We hypothesize that the increase in functional recovery in response to chronic L-isoserine treatment
(indicated by the gray boxes) from day 7 and onwards is mediated by an increase in GAT3 surface expression already from day 7, which
ultimately leads to a greater removal of ambient GABA by GAT3-mediated uptake leading to a decrease in tonic inhibition.
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in motor function when discontinued after at day 32
post-stroke, indicating that L-isoserine induces lasting
plastic changes in the brain. The L-isoserine treatment
was initiated at a delay (5 days) post-stroke at the time
of the critical period for neuroplasticity in rodents40
and within the time window where positive effects of
lowered tonic inhibition via the a5-containing GABAA
receptors using L-655,708 have been reported in respect
to post-stroke recovery.6,11 Thus, this study supports
that increased recovery of function following stroke
can be achieved not only by dampening tonic inhibition
directly by targeting extrasynaptic GABAA recep-
tors6,11 but also through a delayed modulation of
GAT3, which could be a putative target for the treat-
ment of stroke.
Ambient GABA levels and tonic inhibition are con-
trolled by the reuptake of GABA into surrounding
astrocytes and neurons via GATs.14,20 We show that
L-isoserine generally increased the level of GAT3
expression when assessed 42 days post-stroke, corres-
ponding to 10 days after discontinuing the treatment.
These data indicate lasting changes in GAT3 expression
following chronic treatment with L-isoserine that pref-
erentially affects the cells furthest away from the ische-
mic core suggesting that palisading astrocytes are less
susceptible to substrate-induced changes in GAT3
expression. While L-isoserine is a substrate for GAT3,
it still allows the transport of GABA, and although
L-isoserine modulates tonic GABA currents in slices
from naı¨ve mice, the effect in animals subjected to
a stroke still remains unknown. However, based on
the data at hand, we hypothesize that L-isoserine
increases the surface expression of GAT3 from day 7,
which leads to an overall increase in GABA uptake via
GAT3, which in turn dampens tonic inhibition and
improves functional recovery (Figure 7). Our previous
findings, showing that a reduction in tonic inhibition via
a5-containing GABAA receptors increases functional
recovery,6 supports this hypothesis, but awaits further
clarification. These studies will indeed be complicated
further, since GAT3 may be functionally impaired in
some regions6 or reversed in reactive astrocytes,38,49
although the latter is doubtful as the resting membrane
potential and GABA reversal potential have been
shown to be unaffected in the peri-infarct region.6
In contrast to the effects of L-isoserine in vivo, we
found no effect of short-term L-isoserine exposure on
GAT3 surface expression in vitro and GABA uptake in
astrocyte cultures. These findings suggest that the
increase in GAT3 expression in the stroke animals in
response to L-isoserine treatment depends both on
chronic exposure as well as factors present in vivo.
However, it remains unclear if the increase in GAT3
expression following in vivo treatment with L-isoserine
was mediated by a transporter-dependent mechanism,
e.g. affecting the degradation of GAT3 or was indir-
ectly linked to enhanced GAT3 activity.
Tonic inhibition is not the only parameter control-
ling stroke recovery and there is a plethora of factors
that influence the outcome besides tonic inhibition per
se. The reactive astrocyte in particular has many roles
in ischemia and is highly involved in the regulation of
the inflammatory response,42 where chronic neuroin-
flammation impede post stroke recovery.50 A recent
study has also shown that reactive astrocytes are
needed for axonal sprouting,41 indicating that some
astrogliosis is necessary for recovery. For this reason,
we also looked at the modulation of the glial scar in the
stroke mice at day 42 and investigated the effect of
L-isoserine. We show that the high concentration of
L-isoserine decreased the GFAP level in the peri-infarct
in layer 5, but not in layer 2/3. Nevertheless, given that
the low concentration of L-isoserine had no effect
on the GFAP level, and the two concentrations of
L-isoserine had similar effects on motor performance
post-stroke questions whether L-isoserine promoted
recovery by enhancing the resolution of the glial scar.
Also, the changes in GFAP and GAT3 expression in
response to L-isoserine treatment do not seem to be
linked, since the change in GFAP occurred in the
peri-infarct region, where the smallest increase in
GAT3 expression was observed.
Conclusion
We show that a photothrombotic stroke to the motor
cortex produces long-lasting effects by reducing the
GAT3 protein level thus impairing the GAT3 uptake,
persisting for as long as 42 days after the ischemic
insult. We are the first to demonstrate that a GAT3
substrate inhibitor, L-isoserine, administered at a
delay post-stroke, increases GAT3 expression and
facilitates an improvement in recovery of the affected
forelimb, presumably through enhanced GABA uptake
via GAT3 potentially dampening tonic inhibition and
hence enabling cortical remapping.
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